Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer

Phosphatidylserine (PS) is often externalized in viable pancreatic cancer cells and is therapeutically targetable using PS-selective drugs. One of the first-line treatments for advanced pancreatic cancer disease, gemcitabine (GEM), provides only marginal benefit to patients. We therefore investigate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther
Autors principals: N’Guessan, Kombo F., Davis, Harold W., Chu, Zhengtao, Vallabhapurapu, Subrahmanya D., Lewis, Clayton S., Franco, Robert S., Olowokure, Olugbenga, Ahmad, Syed A., Yeh, Jen Jen, Bogdanov, Vladimir Y., Qi, Xiaoyang
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403342/
https://ncbi.nlm.nih.gov/pubmed/32516572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.05.013
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars